Current Management of Unresectable Non-Small-Cell Lung Cancer

ONCOLOGY

Volumn 11, Issue 10 SUPPL. 11, 1997, Pages 11-15

  Livingston, Robert B ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONFERENCE PAPER; HUMAN; LUNG NON SMALL CELL CANCER;

EID: 0030785451     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Wingo PA, Tong T, Bolden S: Cancer statistics, 1995, CA Cancer J Clin 45:8-30, 1995.
2. Dillman RO, Seagren SL, Propert KJ, et al: A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small cell lung cancer. N Engl J Med 323:940-945, 1990.
3. Dillman RO, Seagren SL, Herndon J, et al: Randomized trial of induction chemotherapy plus radiation therapy vs RT alone in stage III nonsmall cell lung cancer: Five year follow up of CALGB. Proc Am Soc Clin Oncol 12:329, 1993.
4. Sause WT, Scott S, Taylor S, et al: Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary results of a phase III trial in regionally advanced, unresectable nonsmall-cell lung cancer. J Natl Cancer Inst 87:198-205, 1995.
5. Rusch VW, Albam KS, Crowley JJ, et al: Surgical resection of stage IIIA and stage IIIB non-small-cell lung cancer after concurrent induction chemoradiotherapy. A Southwest Oncology Group trial. J Thorac Cardiovasc Surg 105,97-106, 1993.
6. Albain KS, Rusch VW, Crowley JJ, et al: Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIA(N2) and IIIB non- small cell lung cancer: Mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 13:1180-1892, 1995.
7. Kies MS, Mira JC, Livingston RB, et al: Multimodal therapy for limited small cell lung cancer. A randomized study of induction combination chemotherapy with or without thoracic radiation in complete respondcrs; and with widefield versus reduced volume radiation in partial responders. A Southwest Oncology Group study. J Clin Oncol 5:592-600, 1987.
8. Strauss GM, Herndon JE, Sherman DD, et al: Induction chemoradiation followed by surgery in stage 1IIA non-small cell carcinoma of the lung (NSCLC): Long term results of Cancer and Leukemia Group B protocol 8634. Proc Am Soc Clin Oncol 15:376, 1996.
9. Albain KS, Crowley JJ, Turrist AT, et al: Concurrent cisplatin/etoposide plus radiotherapy for pathologic stage IIIB NSCLC. A SWOG phase II study (S 9019). Proc Am Soc Clin Oncol 16:446, 1997.
10. Rapp E, Pater JL, Willan A, et al: Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer-Report of a Canadian multicenter randomized trial. J Clin Oncol 6:633-641, 1988.
11. Costanzi JJ, Gagliano R, Loukas D, et al: Ifosfamide in the treatment of recurrent or disseminated lung cancer. Cancer 41:1715-1719, 1978.
12. Leohrer PJ, Birch R, Kramer BS, et al: Ifosfamide plus N-acetylcysteine in treatment of small cell and non-small cell carcinoma of the lung: A Southeastern Cancer Study Group trial. Cancer Treat Rep 70:919-920, 1986.
13. Bonomi PD, Finkelstein DM, Ruckdeschel JC, et al: Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small cell lung cancer: A study of the Eastern Cooperative Group. J Clin Oncol 7:1602-1613, 1989.
14. Gandara DR, Crowley J, Livingston RB, et al: Evaluation of cisplatin intensity in metastatic non-small cell lung cancer: A phase III study of the Southwest Oncology Group. J Clin Oncol 11:873-878, 1993.
15. Depierre A, Lebeau B, Chastang C, et al: Result of a phase III randomized study of vinorelbine vs. vinorelbine-cisplatin in non-small cell lung cancer. Proc Am Soc Clin Oncol 12:340, 1993.
16. O'Rourke M. Crawford J, Schiller J, et al: Survival advantage for patients with stage IV NSCLC treated with single agent Navelbine in a randomized controlled trial. Proc Am Soc Clin Oncol 12:343, 1993.
17. Le Chevalier T, Brisgand D, Douillard JY, et al: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients. J Clin Oncol 12:360-367, 1994.
18. Wozniak AJ, Crowley JJ, Balcerzak SP, et al: Randomized phase III trial of cisplatin vs. cisplatin plus Navelbine in treatment of advanced non-small cell lung cancer: Report of a Southwest Oncology Group study (SWOG 9308). Proc Am Soc Clin Oncol 15:374, 1996.
19. Murphy WK, Fossella FV, Winn RJ, et al: Phase II study of Taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 85:384-388, 1993.
20. Chang A. Kim K, Click J, et al: Phase II study of Taxol, merbarone, and piroxantrone in stage IV non-small cell lung cancer: The Eastern Cooperative Oncology Group results. J Natl Cancer Inst 85:388-394, 1993.
21. Belli L, Le Chevalier T, Gottfried M, et al: Phase I-II trial of paclitaxel and cisplatin in previously untreated advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 14:350, 1995.
22. Bonomi P, Kim K, Chang A, et al: Phase III trial comparing etoposide/cisplatin ± GCSF in advanced NSCLC. An ECOG trial. Proc Am Soc Clin Oncol 15:382, 1996.
23. Vafai D, Israel V, Zaretsky S, et al: Phase I/ II trial of combination carboplatin and Taxol in non-small cell lung cancer. Proc Am Soc Clin Oncol 14:352, 1995.
24. Rowinsky EK, Sartorious SE, Bowling MK, et al: Paclitaxel on a 3-hour schedule and carboplatin in non small cell lung cancer- Use of maximally tolerated and clinically relevant single agent doses in combination is feasible. Proc Am Soc Clin Oncol 14:354, 1995.
25. Paul D, De Vore RD, Hande K, et al: Phase II trial of carboplatin + paclitaxel in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 14:361, 1995.
26. Langer CJ, Leighton JC, Comis RL, et al: Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung can cer: A phase II toxicity, response, and survival analysis. J Clin Oncol 13:1860-1870, 1995.
27. Fossella FV, Lee JS, Shin DM: Phase II study of docetaxel for advanced or melastalic platinum-refractory non-small-cell lung cancer. J Clin Oncol 13:645-651, 1995.
28. Burris H, Eckardt J, Fields S, et al: Phase II trials of Taxotere in patients with non-small cell lung cancer. Proc Am Soc Clin Oncol 12:335, 1993.
29. Fossella VF, Lippman S, Pang A, et al: Phase I/II study of gemcitabine by 30 minute weekly intravenous infusion x 3 weeks every 4 weeks for non-small cell lung cancer. Proc Am Soc Clin Oncol 14:326, 1995.
30. Shepherd FA, Gatzemeier U, Gotfried M, et al: An extended phase II study of gemcitabine in non small cell lung cancer. Proc Am Soc Clin Oncol 12:330, 1993.
31. Abratt R, Bezwoda W, Falkson G, et al: Efficacy and safety of gemcitabine in non small cell lung cancer. Phase II study results. Proc Am Soc Clin Oncol 12:338, 1993.
32. Antón A, Carrato A, González Larriba JL, et al: Phase II activity of gemcitabine in combina- tion with cisplatin in advanced non small cell lung cancer. Proc Am Soc Clin Oncol 15:380, 1996
33. Shepherd F, Cormier Y, Evans W, et al: A phase II study of gemcitabine and cisplatin weekly x 3 every 4 weeks in patients with non-small cell lung cancer. Proc Am Soc Clin Oncol 15:380, 1996.
34. Abratt RP, Bezwoda WR, Goedlhals L, et al: Gemcitabine and cisplatin for advanced nonsmall cell lung cancer. Proc Am Soc Clin Oncol 15:380, 1996.
35. Fukuoka M, Niitani H, Suzuki A, et al: A phase II study of CPT-11, a new derivative of camptothecin for previously untreated non-small-cell lung cancer. J Clin Oncol 10:16-20, 1992.
36. Nakagawa K, Fukuoka M, Niitani H, and the CPT-11 Lung Cancer Study Group: Phase II study of irinotecan (CPT-11) and cisplatin in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 12:332, 1993.
37. Shinkai T, Arioka H, Kunikane H, et al: A phase I study of CPT-11 and cisplatin in combination with fixed dose of vindesine in metastatic non-small cell lung cancer. Proc Am Soc Clin Oncol 12:328, 1993.
38. Perez-Soler R, Fossella FV, Glisson BS, et al: Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. J Clin Oncol 14:503-513, 1996.